Plasma viral load threshold for sustaining intrahost HIV type 1 evolution

AIDS Research and Human Retroviruses

Volumn 23, Issue 10, 2007, Pages 1242-1250

  Bello, Gonzalo ^a   Casado, Concepción ^b   Sandonis, Virginia ^b   Alvaro Cifuentes, Tamara ^b   Dos Santos, Caio A Rodrigues ^a   García, Soledad ^c   Rodríguez, Carmen ^c   Del Romero, Jorge ^c   Pilotto, José H ^d   Grinsztejn, Beatriz ^d   Veloso, Valdilea G ^d   Morgado, Mariza G ^a   López Galíndez, Cecilio ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO SANITARIO SANDOVAL   (Spain)

^d Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ALLOTYPE SUPPRESSION; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENVELOPE GENE; EVOLUTION; FEMALE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERM NONPROGRESSOR; MALE; PATIENT CODING; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; RNA VIRUS; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; EVOLUTION, MOLECULAR; FEMALE; GENES, ENV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 35548993311     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0074     Document Type: Article

References (55)

1. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, and Meyer L: Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: An uncommon phenomenon? Clin Infect Dis 2005;40:1350-1354.
2. Madec Y, Boufassa F, Porter K, and Meyer L: Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005;19:2001-2007.
3. Lefrere JJ, Mariotti M, Morand-Joubert L, Thauvin M, and Roudot-Thoraval F: Plasma human immunodeficiency virus RNA below 40 copies/mL is rare in untreated persons even in the first years of infection. J Infect Dis 1999;180:526-529.
4. Hubert JB, Burgard M, Dussaix E, et al.: Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000;14:123-131.
5. Goudsmit J, Bogaards JA, Jurriaans S, et al.: Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS 2002;16:791-793.
6. Lefrere JJ, Morand-Joubert L, Mariotti M, et al.: Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997;90:1133-1140.
7. Lambotte O, Boufassa F, Madec Y, et al.: HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41:1053-1056.
8. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, and Saksena NK: First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 2003;312:135-150.
9. Bello G, Casado C, Sandonis V, et al.: A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population. J Gen Virol 2005;86:355-364.
10. Gunthard HF, Wong JK, Ignacio CC, et al.: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
11. Karlsson AC, Birk M, Lindback S, Gaines H, Mittler JE, and Sonnerborg A: Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. AIDS Res Hum Retroviruses 2001;17:409-416.
12. Hermankova M, Ray SC, Ruff C, et al.: HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 2001;286:196-207.
13. Ruff CT, Ray SC, Kwon P, et al.: Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-9492.
14. Persaud D, Siberry GK, Ahonkhai A, et al.: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78:968-979.
15. Kieffer TL, Finucane MM, Nettles RE, et al.: Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004;189:1452-1465.
16. Nettles RE, Kieffer TL, Kwon P, et al.: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-829.
17. Gunthard HF, Frost SD, Leigh-Brown AJ, et al.: Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-9412.
18. Martinez-Picado J, DePasquale MP, Kartsonis N, et al.: Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000;97:10948-10953.
19. Frost SD, Gunthard HF, Wong JK, Havlir D, Richman DD, and Leigh Brown AJ: Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology 2001;284:250-258.
20. Gunthard HF, Havlir DV, Fiscus S, et al.: Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001;183:1318-1327.
21. Cohen Stuart JW, Wensing AM, Kovacs C, et al.: Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001;28:105-113.
22. Frenkel LM, Wang Y, Learn GH, et al.: Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003;77:5721-5730.
23. Tobin NH, Learn GH, Holte SE, et al.: Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol 2005;79:9625-9634.
24. Zhang L, Ramratnam B, Tenner-Racz K, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
25. Birk M, Aleman S, Visco-Comandini U, and Sonnerborg A: Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy. HIV Med 2000;1:205-211.
26. Riva E, Pistello M, Narciso P, et al.: Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001;17:1599-1604.
27. Bello G, Casado C, Garcia S, Rodriguez C, del Romero J, and Lopez-Galindez C: Co-existence of recent and ancestral nucleotide sequences in viral quasispecies of human immunodeficiency virus type 1 patients. J Gen Virol 2004;85:399-407.
28. Bello G, Casado C, Garcia S, et al.: Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naive patients. Virology 2007;362:294-303.
29. Rodrigo AG, Goracke PC, Rowhanian K, and Mullins JI: Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses 1997;13:737-742.
30. Delwart EL, Shpaer EG, Louwagie J, et al.: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
31. Tanuri A, Swanson P, Devare S, et al.: HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:60-66.
32. Casado C, Garcia S, Rodriguez C, del Romero J, Bello G, and Lopez-Galindez C: Different evolutionary patterns are found within human immunodeficiency virus type 1-infected patients. J Gen Virol 2001;82:2495-2508.
33. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG: The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
34. Kumar S, Tamura K, and Nei M: MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
35. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-10502.
36. Wolinsky SM, Korber BT, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
37. Menzo S, Sampaolesi R, Vicenzi E, et al.: Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. AIDS 1998;12:985-997.
38. Bagnarelli P, Mazzola F, Menzo S, Montroni M, Butini L, and Clementi M: Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol 1999;73:3764-3777.
39. Wang B, Spira TJ, Owen S, Lal RB, and Saksena NK: HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. AIDS 2000;14:213-223.
40. Markham RB, Wang WC, Weisstein AE, et al.: Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci USA 1998;95:12568-12573.
41. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
42. Persaud D, Pierson T, Ruff C, et al.: A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000;105:995-1003.
43. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727-728.
44. Greub G, Cozzi-Lepri A, Ledergerber B, et al.: Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002;16:1967-1969.
45. Strunnikova N, Ray SC, Livingston RA, Rubalcaba E, and Viscidi RP: Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol 1995;69:7548-7558.
46. Mani I, Gilbert P, Sankale JL, Eisen G, Mboup S, and Kanki PJ: Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection. J Virol 2002;76:10745-10755.
47. Mikhail M, Wang B, Lemey P, et al.: Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology 2005;2:41.
48. Lukashov VV, Kuiken CL, and Goudsmit J: Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol 1995;69:6911-6916.
49. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, and Wolinsky SM: Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 1997;71:663-677.
50. Liu SL, Schacker T, Musey L, et al.: Divergent patterns of progression to AIDS after infection from the same source: Human immunodeficiency virus type 1 evolution and antiviral responses. J Virol 1997;71:4284-4295.
51. Shioda T, Oka S, Xin X, et al.: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: Association of V2 extension with slow disease progression. J Virol 1997;71:4871-4881.
52. Delwart EL, Pan H, Sheppard HW, et al.: Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-7508.
53. Zhang L, Diaz RS, Ho DD, Mosley JW, Busch MP, and Mayer A: Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol 1997;71:2555-2561.
54. Bello G, Casado C, Garcia S, et al.: Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection. Arch Virol 2004;149:1761-1771.
55. Grenfell BT, Pybus OG, Gog JR, et al.: Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004;303:327-332.